Rubraca: payments to doctors
Payments that named Rubraca as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $3M
- Providers
- 4,743
- Transactions
- 13,077
- Average per transaction
- $226
The per-transaction average — $226 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,743 providers the average total is $623, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Clovis Oncology, Inc. | $2,855,620 | 96.7% |
| Pharmaand GmbH | $70,569 | 2.4% |
| Tolmar, Inc. | $28,266 | 1.0% |